Vizsgálati helyszín
Wichita Urology Group
Wichita, Kansas 67226, Egyesült ÁllamokMég nincs intézményhez kötve
- 13futó vizsgálat
- 1lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 14 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis9 vizsgálat
- 2. fázis2 vizsgálat
- 1. fázis1 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz7 vizsgálat
- Toboroz6 vizsgálat
- Lezárult1 vizsgálat
- Fő szponzor
- Janssen Research & Development, LLC4 vizsgálat
- CG Oncology, Inc.2 vizsgálat
- Ferring Pharmaceuticals2 vizsgálat
- Astellas Pharma Global Development, Inc.1 vizsgálat
- Bayer1 vizsgálat
- és még 4
Futó vizsgálatok
Toboroz
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
NCT06545955· 3. fázis· Ferring Pharmaceuticals· Forrás
Contact: Ferring Pharmaceuticals
Toboroz
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06510374· 3. fázis· Ferring Pharmaceuticals· Forrás
Contact: Ferring Pharmaceuticals
Toboroz
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
NCT06567743· 2. fázis· CG Oncology, Inc.· Forrás
Contact: Philippe Nabbout, MD
Toboroz
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
NCT06056830· 3. fázis· Clarity Pharmaceuticals Ltd· Forrás
Contact: Timothy Richardson, MD
Fut, nem toboroz
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235· 3. fázis· CG Oncology, Inc.· Forrás
Fut, nem toboroz
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
NCT05491525· 2/3. fázis· Urovant Sciences GmbH· Forrás
Contact: Kahlil N Saad (principal investigator)
Fut, nem toboroz
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
NCT05243550· 3. fázis· UroGen Pharma Ltd.· Forrás
Toboroz
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
NCT04729114· 1. fázis· Astellas Pharma Global Development, Inc.· Forrás
Contact: Astellas Pharma Global Development, Inc.
Fut, nem toboroz
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
NCT04122976· Bayer· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek